The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Macro EconomyMedium•6 March 2026•

1 min read

FDA to Introduce Bonuses to Slash Drug Approval Times Amid Staffing Shortages

Emmanuel Macron's face centered between cracked Visa and Mastercard cards, with Euro and Ethereum symbols, bank buildings, and digital payment cards.

Key Facts

1The US FDA lost about 20% of its workforce since Trump took office.

2The agency aims to shrink drug approval times from 29 months to as low as 6 months.

The US Food and Drug Administration (FDA) is launching a new incentive program designed to significantly accelerate the drug approval process. Under the new plan, the agency aims to reduce review times from the current average of 29 months to as little as 6 months. To achieve this, financial bonuses will be offered to staff members to incentivize expedited reviews, addressing a critical 20% reduction in the workforce since the start of the Trump administration. This move toward deregulation is expected to lower R&D overhead and accelerate revenue cycles for pharmaceutical companies by shortening the path to commercialization. Market analysts view this development as a major tailwind for the healthcare and biotech sectors, potentially boosting major instruments such as XLV, IBB, and leading drugmakers.